ASH 2021 | Assessing treatment regiments in patients from the informCLL registry
Jacqueline Barrientos
• 13 Dec 2021
Jacqueline Barrientos, MD, MS, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, presents findings from an analysis of the informCLL Real-World Registry, which enrolled patients with chronic lymphocytic leukemia (CLL). Patient care was compared with current National Comprehensive Cancer Network (NCCN) Guidelines. Detection of 17p and TP53 mutations were found to be inadequate in the cohort, which resulted in the aforementioned patients erroneously receiving chemoimmunotherapy. Dr Barrientos highlights the importance of testing for mutations, as well as the use of targeted therapies such as ibrutinib and acalabrutinib. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
